Churg-Strauss syndrome natural history, complications and prognosis

Jump to navigation Jump to search

Churg-Strauss syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Churg-Strauss syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Churg-Strauss syndrome natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Churg-Strauss syndrome natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Churg-Strauss syndrome natural history, complications and prognosis

CDC on Churg-Strauss syndrome natural history, complications and prognosis

Churg-Strauss syndrome natural history, complications and prognosis in the news

Blogs on Churg-Strauss syndrome natural history, complications and prognosis

Directions to Hospitals Treating Churg-Strauss syndrome

Risk calculators and risk factors for Churg-Strauss syndrome natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Natural History

Classically, three phases of the disease are described:

Stage 1: The Prodromal Phase

This stage occurs in the teenage years through the 20’s. The first stage often involves the sinuses and the new onset of allergies or the worsening of pre-existing allergies (e.g. atopic diseases, allergic rhinitis).

Stage 2: The Eosinophilic Phase

Peripheral blood eosinophilia is now present. There is eosinophilic infiltration of lung and gastrointestinal (GI) tract. The second stage involves the onset of acute asthma. Normally, the person would not have had asthma previously.

People can live for many years in the first two stages before progressing to stage three.

Stage 3: The Vasculitic Phase

The third phase occurs in the 40’s-50’s and involves multiple organ systems in a life-threatening systemic vasculitis of small and medium sized vessels. Stage three is by far the most life threatening and painful. Often the person will develop severe nerve pain in their legs, arms and hands. Purple marks will appear on the skin and often sores will appear in the mouth or nose. The disease will affect the heart and lungs or it will affect the kidneys and liver.

Complications

Complications of Churg-Strauss syndrome depend on the specific organ involved in the disease process.

Prognosis

  • Churg-Strauss syndrome is a serious disease that can be fatal if untreated.
  • Untreated patients have a 5 yr survival rate of 20%-30%

Prior to the steroid treatment, the disease was uniformly fatal. Now, 5 year survival tops 70%. In general, poor prognostic indicators include cardiac involvement, GI disease, renal insufficiency (Cr >1.6), proteinuria (>1 g/day) and central nervous system (CNS) involvement. A shorter duration of asthma before the onset of vasculitis also portends poorer prognosis. The role of anti-neutrophil cytoplasmic antibodies (ANCA) in predicting outcome is unclear.

The French Vasculitis Study Group has developed a five-point score ("five-factor score" or FFS) that predicts the risk of death in Churg-Strauss syndrome. These are

(1) reduced renal function (creatinine >1.58 mg/dL or 140 μmol/l),

(2) proteinuria (>1 g/24h),

(3) gastrointestinal hemorrhage, infarction or pancreatitis,

(4) involvement of the central nervous system or

(5) cardiomyopathy.

Presence of 1 of these indicates severe disease (5-year mortality 26%) and 2 or more very severe disease (mortality 46%), while absence of any of these 5 indicates a milder case (mortality 11.9%).[1]

References

  1. Guillevin L, Lhote F, Gayraud M; et al. (1996). "Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients". Medicine (Baltimore). 75 (1): 17–28. PMID 8569467.

Template:WH Template:WS